NYSE
$103.77▲ 0.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $180.75BShares out 17.400M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
16- 4d agoPre-market26.10.21 22:198-KKey event#●●●#●●●
ABBOTT LABORATORIES
Abbott Laboratories has announced its intention to separate its global Nutrition business into an independent, publicly traded company by the end of 2027. The separation will be executed through a tax-free distribution of shares to existing Abbott shareholders. Post-separation, Abbott will focus on its core medical device and diagnostics portfolio, while the new nutrition entity will operate as a standalone company with approximately $8.5 billion in annual sales.…more
$103.77+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 4d agoPre-market26.10.21 20:368-KKey event
ABBOTT LABORATORIES
Abbott Laboratories reported third-quarter 2026 sales of $13.013 billion and GAAP diluted EPS of $0.53. The company reaffirmed its full-year 2026 adjusted diluted EPS guidance, tightening the range to $5.50 to $5.55, and declared a quarterly dividend of $0.63 per share.…more
$103.77+0.05%vs prev closeView filingShare - 10.2After-hours26.10.03 05:114Ownership
ABBOTT LABORATORIES
John G. Stratton, an independent director of Abbott Laboratories, reported a change in beneficial ownership of company securities effective September 30, 2026. This filing serves as an official notification to the SEC regarding the insider's equity position.…more
$103.77+0.05%vs prev closeView filingShare
15 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoPre-market26.10.23 22:17#●●●#●●●
Abbott Reports 30% Improvement in Colorectal Cancer Recurrence Detection…more
Abbott announced new clinical data at the ESMO Congress showing its molecular residual disease test improved sensitivity for colorectal cancer recurrence by 30% compared to previous methods. The study validates the effectiveness of the test in tracking residual disease through post-surgery blood samples.…more
$103.77+0.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 3d agoRegular26.10.22 02:00
●●●●●●●● ●●●●● ●●●●●●
Abbott plans to spin off its nutrition business by 2027 to enhance shareholder value, but shares fell following a lowered sales growth forecast. While the company ruled out a sale, concerns over slowing growth in its medical device and diabetes segments weighed on the outlook.…more
$103.77+0.05%vs prev closeShareBenzinga - 3d agoRegular26.10.21 22:43
●●●●●●●● ●●●●● ●●●●●●
Abbott executives stated that the company does not need to fully resolve ongoing litigation to complete the separation of its nutrition business. This suggests that the spin-off process can proceed independently of the current legal disputes.…more
$103.77+0.05%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report